EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, TGTX: Tg Therapeutics

01 May 26 15:59
LAST:

33.83

CHANGE:
 0.07		OPEN:
33.71		HIGH:
34.05		ASK:
6.55		VOLUME:
850.3K
CHG(%):
0.21		PREV:
33.78		LOW:
33.23		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
01 May 2633.8634.0533.2333.851.5M
30 Apr 2633.5834.2533.3933.781.38M
29 Apr 2634.0234.1933.2833.581.83M
28 Apr 2635.6036.0134.4434.582.27M
27 Apr 2636.7136.9934.9935.381.66M
24 Apr 2636.8937.1536.2836.621.37M
23 Apr 2638.3438.3836.6136.921.86M
22 Apr 2636.4838.3236.2538.312.3M
21 Apr 2636.9437.2436.0736.282.08M
20 Apr 2635.1737.1635.1636.962.48M

PROFILE

Name:Tg Therapeutics
About:TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Sector:Healthcare
Industry:Biotechnology
Address:3020 Carrington Mill Blvd., Morrisville, NC, United States, 27560
Website:https://www.tgtherapeutics.com
CUSIP:048785109
CIK:0001001316
ISIN:US88322Q1085
FIGI:BBG000FVZQY1
LEI:529900X21UKABN9NJ529

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:12.29 
Forward P/E:13.83 
Price to Sales:12.83 
Price to Book:7.53 
EPS Ratio:2.77 
Revenue:454.07M 
EBITDA:85.89M 
Shares:159.69M 
Market Cap:5.402B 

TECHNICAL INDICATORS

MA5:34.231.2%
MA10:35.635.3%
MA20:34.923.2%
MA50:32.115.3%
MA100:31.078.9%
MA200:31.876.2%
STO9:5.63 
STO14:5.63 
RSI14:50.26
WPR14:-94.29 
MTM14:-0.71
ROC14:-0.02 
ATR:1.32 
Week High:37.159.8%
Week Low:33.231.8%
Month High:38.3813.4%
Month Low:33.056.2%
Year High:46.4837.4%
Year Low:25.2833.8%

RECENT SPLITS

Date Ratio
30 Apr 2012100-5625
14 Jul 20111-50